TB R&D Update: New treatment strategy using Bedaquiline in combination with heart medication, Verapamil

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model‘ was recently published in Antimicrobial Agents and Chemotherapy.

Although Bedaquiline is an effective anti-tuberculosis agent, it has significant liver and heart toxicity. Supplementing bedaquiline treatment in mice models with verapamil reduced not only the dosage required and thus toxicity, but also the emergence of antibiotic resistance, without sacrificing potency.

Scientists at the Tuberculosis Research Center plan to use this new data to design clinical trials.

Related Links

Verapamil Increases the Bactericidal Activity of Bedaquiline Against Mycobacterium tuberculosis in the Mouse Model

Study indicates new strategy to treat tuberculosis

New treatment strategy allows lower doses of toxic tuberculosis drug without compromising potency

Additional Links

Sirturo approved for conditional use in European Union to treat MDR-TB in adults

Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

More News
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Center for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...
11 Aug 2020
The European Commission (EC) has provided conditional marketing authorization for pretomanid, a novel compound developed by TB Alliance, when used in combination with bedaquiline and linezolid as part of a six month, all-oral regimen for the treatment of adults with XDR-TB or treatment-intolerant...
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...